|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM100141099 |
| 003 |
DE-627 |
| 005 |
20250201035257.0 |
| 007 |
tu |
| 008 |
231222s1999 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0334.xml
|
| 035 |
|
|
|a (DE-627)NLM100141099
|
| 035 |
|
|
|a (NLM)10080830
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Pérez Leirós, C
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Activation of nitric oxide signaling through muscarinic receptors in submandibular glands by primary Sjögren syndrome antibodies
|
| 264 |
|
1 |
|c 1999
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.03.1999
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 1999 Academic Press.
|
| 520 |
|
|
|a Primary Sjögren Syndrome is a chronic autoimmune disease characterized by exocrine gland dysfunction. Here we present evidence of the activation of nitric oxide signaling cascade by circulating antibodies of patients with Sjögren Syndrome in rat submandibular glands. Constitutive nitric oxide synthase and cyclic GMP levels are modulated by Sjögren IgGs through the activation of muscarinic acetylcholine receptors on the glands. The effects are similar to those produced by the agonist carbachol and blocked by the antagonist atropine. The involvement of M1 subtype of muscarinic receptors is proposed since both a synthetic peptide homologous to an extracellular domain of M1 receptor and pirenzepine, a selective M1 antagonist, partially blocked the effects. We conclude that Sjögren Syndrome antibodies can activate nitric oxide signaling in submandibular glands by interacting with muscarinic acetylcholine receptors
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Autoantibodies
|2 NLM
|
| 650 |
|
7 |
|a Autoantigens
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Receptor, Muscarinic M1
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Muscarinic
|2 NLM
|
| 650 |
|
7 |
|a Nitric Oxide
|2 NLM
|
| 650 |
|
7 |
|a 31C4KY9ESH
|2 NLM
|
| 700 |
1 |
|
|a Sterin-Borda, L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hubscher, O
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arana, R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Borda, E S
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 90(1999), 2 vom: 19. Feb., Seite 190-5
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:90
|g year:1999
|g number:2
|g day:19
|g month:02
|g pages:190-5
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 90
|j 1999
|e 2
|b 19
|c 02
|h 190-5
|